Furthermore, compared with placebo, liraglutide treatment decreased leptin by 20% and liver fat content by 44%, thus supporting a specific effect on hepatic ectopic fat
Large-scale clinical trials have demonstrated that GLP-1RAs predominantly exhibit neutral or suppressive effects on overall cancer risk, with semaglutide showing no elevated cancer incidence [14], while significant reductions have been observed in specific malignancies, particularly liver cancers and prostate cancers [13, 15]
Aids sustainable weight management
Readers are advised to check the MHRA and NICE websites regularly, as the regulatory and commissioning position may change
So thats such a valuable way to, I think, organize our biochemical thinking around that